Keck USC 13th Annual USC Multidisciplinary Breast Cancer Symposium 2026

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Surgical Oncologists (Breast Surgical Oncologists), Medical Oncologists, Radiation Oncologists, Breast Imaging Radiologists, Reproductive Endocrinologists (Infertility / Oncofertility Specialists), Plastic and Reconstructive Surgeons, Pathologists, and Primary Care Physicians

+ Sample video: contact me for sample video

+ Information:

This program reviews the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include oncofertility, breast pathology, surgical oncology, medical oncology, and radiation oncology. The format of this program consists of lectures by international experts in their fields.

Over the past year, advances in clinical trials have demonstrated the utility of antibody-drug conjugates, molecular detection of residual disease, and downstaging surgical management of the axilla. These developments, along with data on resistance to endocrine therapy, updates in the use of artificial intelligence in breast cancer detection and diagnostics, therapy targeting the HER2 axis, and breast cancer risk in patients having gender affirming surgery, make individualized management decisions increasingly important in treating patients with breast cancer. Newer radiation therapy treatment strategies and clinical trials in radiation oncology continue to evolve. These breakthroughs allow personalized breast cancer treatments to maximize benefits and minimize treatment toxicities.

The symposium focuses on advances in neoadjuvant adjuvant hormone therapy, new hormone receptors in breast cancer, surgical management of the axilla, clinical trials in radiation therapy, oncofertility, the use of identifying circulating tumor DNA in the blood after treatment, and evolving strategies in HER2-positive breast cancer.

Learning Objectives

By the end of the course, participants will be able to:

• Understand the role of novel diagnostic tools for breast cancer including ctDNA and AI.

• Assess the risk of breast cancer in patients undergoing gender-affirming care.

• Explain the importance of fertility preservation during breast cancer treatment.

• Discuss appropriate use of ADCs and HER2-directed therapies.

• Identify the controversies regarding the role of radiation therapy in DCIS.

• Assess decision-making process in surgical management of the axilla.

• Incorporate the evolving role of clinical trials in radiation therapy.

• Define the role of neoadjuvant and novel endocrine therapy.

• Recognize an evolving role of Androgen and Glucocorticoid Receptors in breast cancer.

Target Audience

This conference is designed for practicing primary care physicians, medical oncologists, radiation oncologists, surgical oncologists, radiologists, residents and fellows in oncology training programs, as well as allied health providers including oncology nurses, mid-level providers (APN and PA), radiation therapists (RTT), and any other clinicians interested or involved in the management and treatment of breast cancer.

Best for Surgical Oncologists (Breast Surgical Oncologists), Medical Oncologists, Radiation Oncologists, Breast Imaging Radiologists, Reproductive Endocrinologists (Infertility / Oncofertility Specialists), Plastic and Reconstructive Surgeons, Pathologists, and Primary Care Physicians.

Topics

• Welcome and Opening Remarks (Eric L. Chang, MD and Lajos Pusztai, MD, D.Phil)

• Session I (Moderator: Jason C. Ye, MD)

  • ctDNA for Breast Cancer (Lajos Pusztai, MD, D.Phil)

  • Evolving Use of Artificial Intelligence for Breast Cancer Detection and Diagnosis (Mary Yamashita, MD)

  • Case Presentation and Discussion (Claire Valburg, MD)

  • Breast Cancer Risk in Patients Undergoing Gender Affirming Surgery (Emily L. Siegel, MD)

  • Case Presentation and Discussion (Seyi Omeh, MD)

  • Fertility Considerations in Breast Cancer Patients (Katherine McDaniel, MD)

  • Case Presentation and Discussion (Amanda Daoud, DO)

• Break

• Session II (Moderator: Daphne Stewart, MD, MS)

  • Biomarkers for Antibody-Drug Conjugates (Samer Alkassis, MD, MS)

  • Update on HER2+-Directed Therapy in Early Breast Cancer (Charles E. Geyer, Jr., MD)

  • Case Presentation and Discussion (Krithika Chennapan, MD)

• Lunch

• Session III (Moderator: Eric L. Chang, MD)

  • Radiation Therapy I – Radiation Therapy for DCIS (Chirag Shah, MD)

  • Who Still Needs Surgical Staging of the Axilla? (Stephen F. Sener, MD)

  • Radiation Therapy II – Role of Regional Node Irradiation: NSABP B-51 (Jason C. Ye, MD)

  • Case Presentation and Discussion (Stephen F. Sener, MD)

• Break

• Session IV (Moderator: Stephen F. Sener, MD)

  • Neoadjuvant Endocrine Therapy (Kelly Hunt, MD)

  • Evolving Role of Androgen and Glucocorticoid Receptors in Breast Cancer (Gini Fleming, MD)

  • Novel Endocrine Agents in Development: Downregulating the Estrogen Receptor (William J. Gradishar, MD)

  • Case Presentation and Discussion (Sara Cartwright, DO)

• Closing Remarks & Adjourn